FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163085807> ?p ?o ?g. }

• W2163085807 endingPage "7024" @default.
• W2163085807 startingPage "7018" @default.
• W2163085807 abstract "Abstract Purpose: Patients with adult acute myeloid leukemia (AML) with intermediate cytogenetics remain a heterogeneous group with highly variable individual prognoses. New molecular markers could help to refine cytogenetic stratification. Experimental Design: We assessed P-glycoprotein (Pgp) activity and Flt3 internal tandem duplication (ITD+) because of their known prognostic value and because they might lead to targeted therapy. We did a multivariate analysis on 171 patients with adult AML treated in the European Organization for Research and Treatment of Cancer protocols. Results: ITD+ and high Pgp activity (Pgp+) were found in 26 of 171 (15%) and 55 of 171 (32%) of all patients, respectively. ITD and Pgp activities were negative in 94 of 171 (55%, Pgp−ITD− group), mutually exclusive in 73 of 171 (43%, Pgp−ITD+ and Pgp+ITD− groups), and only 4 of 171 (2%, Pgp+ITD+ group) patients were positive for both. In multivariate analyses, Pgp+ITD+ (P &lt; 0.0001) and age (P = 0.0022) were independent prognostic factors for the achievement of complete remission (CR). Overall survival (OS), CR achievement (P &lt; 0.0001), WHO performance status (P = 0.0007), and Pgp+ITD+ status (P = 0.0014) were also independent prognostic factors. In 95 patients with intermediate cytogenetics, the CR rates of ITD+ patients were 40% versus 62% for ITD− (P = 0.099) and 41% versus 67% (P = 0.014) for Pgp+ versus Pgp− patients. In the Pgp−ITD− group (41 of 95), CR rates were 70% versus 44% for others (P = 0.012), OS achieved 48% versus 16% (P &lt; 0.0001) and disease-free survival was 56% versus 27% (P = 0.024), respectively. Furthermore, the OS curves of the intermediate cytogenetics-Pgp−ITD− group were not significantly different from the favorable cytogenetic group. Conclusion: Flt3/ITD and Pgp activity are independent and additive prognostic factors which provide a powerful risk classification that can be routinely used to stratify the treatment of patients with intermediate cytogenetic AML. ITD+ and Pgp+ patients should be considered for targeted therapy." @default.
• W2163085807 created "2016-06-24" @default.
• W2163085807 creator A5009857596 @default.
• W2163085807 creator A5018579898 @default.
• W2163085807 creator A5018804969 @default.
• W2163085807 creator A5026913165 @default.
• W2163085807 creator A5031685529 @default.
• W2163085807 creator A5043175279 @default.
• W2163085807 creator A5052150142 @default.
• W2163085807 creator A5072099748 @default.
• W2163085807 creator A5077341645 @default.
• W2163085807 date "2006-12-01" @default.
• W2163085807 modified "2023-10-04" @default.
• W2163085807 title "Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia" @default.
• W2163085807 cites W1489323849 @default.
• W2163085807 cites W1706395004 @default.
• W2163085807 cites W1930980342 @default.
• W2163085807 cites W1964724251 @default.
• W2163085807 cites W1989604472 @default.
• W2163085807 cites W1990030298 @default.
• W2163085807 cites W1991509879 @default.
• W2163085807 cites W2006116919 @default.
• W2163085807 cites W2008735841 @default.
• W2163085807 cites W201908734 @default.
• W2163085807 cites W2020930633 @default.
• W2163085807 cites W2038201387 @default.
• W2163085807 cites W2041027929 @default.
• W2163085807 cites W2051743028 @default.
• W2163085807 cites W2065201141 @default.
• W2163085807 cites W2078357711 @default.
• W2163085807 cites W2082408605 @default.
• W2163085807 cites W2091623943 @default.
• W2163085807 cites W2106473110 @default.
• W2163085807 cites W2117154060 @default.
• W2163085807 cites W2117499535 @default.
• W2163085807 cites W2125695832 @default.
• W2163085807 cites W2125877707 @default.
• W2163085807 cites W2129615499 @default.
• W2163085807 cites W2129951747 @default.
• W2163085807 cites W2132912591 @default.
• W2163085807 cites W2140847482 @default.
• W2163085807 cites W2143297156 @default.
• W2163085807 cites W2148047805 @default.
• W2163085807 cites W2150470057 @default.
• W2163085807 cites W2151222524 @default.
• W2163085807 cites W2153345005 @default.
• W2163085807 cites W2156911730 @default.
• W2163085807 cites W2157228099 @default.
• W2163085807 cites W2158625802 @default.
• W2163085807 cites W2162700652 @default.
• W2163085807 cites W2164886552 @default.
• W2163085807 cites W2167228936 @default.
• W2163085807 cites W2170515966 @default.
• W2163085807 cites W2325902709 @default.
• W2163085807 cites W2764775166 @default.
• W2163085807 cites W3026038204 @default.
• W2163085807 cites W4246142716 @default.
• W2163085807 cites W4250174637 @default.
• W2163085807 doi "https://doi.org/10.1158/1078-0432.ccr-06-0641" @default.
• W2163085807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17145823" @default.
• W2163085807 hasPublicationYear "2006" @default.
• W2163085807 type Work @default.
• W2163085807 sameAs 2163085807 @default.
• W2163085807 citedByCount "23" @default.
• W2163085807 countsByYear W21630858072012 @default.
• W2163085807 countsByYear W21630858072013 @default.
• W2163085807 countsByYear W21630858072014 @default.
• W2163085807 countsByYear W21630858072015 @default.
• W2163085807 countsByYear W21630858072019 @default.
• W2163085807 countsByYear W21630858072020 @default.
• W2163085807 countsByYear W21630858072021 @default.
• W2163085807 countsByYear W21630858072022 @default.
• W2163085807 countsByYear W21630858072023 @default.
• W2163085807 crossrefType "journal-article" @default.
• W2163085807 hasAuthorship W2163085807A5009857596 @default.
• W2163085807 hasAuthorship W2163085807A5018579898 @default.
• W2163085807 hasAuthorship W2163085807A5018804969 @default.
• W2163085807 hasAuthorship W2163085807A5026913165 @default.
• W2163085807 hasAuthorship W2163085807A5031685529 @default.
• W2163085807 hasAuthorship W2163085807A5043175279 @default.
• W2163085807 hasAuthorship W2163085807A5052150142 @default.
• W2163085807 hasAuthorship W2163085807A5072099748 @default.
• W2163085807 hasAuthorship W2163085807A5077341645 @default.
• W2163085807 hasConcept C104317684 @default.
• W2163085807 hasConcept C126322002 @default.
• W2163085807 hasConcept C143998085 @default.
• W2163085807 hasConcept C156446351 @default.
• W2163085807 hasConcept C174475383 @default.
• W2163085807 hasConcept C2483381 @default.
• W2163085807 hasConcept C2778461978 @default.
• W2163085807 hasConcept C2778729363 @default.
• W2163085807 hasConcept C30481170 @default.
• W2163085807 hasConcept C38180746 @default.
• W2163085807 hasConcept C53226629 @default.
• W2163085807 hasConcept C54355233 @default.
• W2163085807 hasConcept C71924100 @default.
• W2163085807 hasConcept C7602840 @default.
• W2163085807 hasConcept C86803240 @default.

• next